Background Myostatin inhibition is a promising therapeutic strategy to maintain muscle mass
in a variety of disorders, including the muscular dystrophies, cachexia, and sarcopenia …

Mutations in myostatin (GDF8) cause marked increases in muscle mass, suggesting that this
transforming growth factor‐β (TGF‐β) superfamily member negatively regulates muscle …

Myostatin is a negative regulator of muscle mass and its inhibition represents a promising
strategy for the treatment of muscle disorders and type 2 diabetes. However, there is …

Increasing the size and strength of muscles represents a promising therapeutic strategy for
musculoskeletal disorders, and interest has focused on myostatin, a negative regulator of …

Myostatin, or GDF-8 (growth and differentiation factor-8), was first identified through
sequence identity with members of the BMP (bone morphogenetic protein)/TGF-β …

In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …

Myostatin was identified more than 20 years ago as a negative regulator of muscle mass in
mice and cattle. Since then, a wealth of studies have uncovered the potential involvement of …

There is much interest in developing anti-myostatin agents to reverse or prevent muscle
atrophy in adults, so it is important to characterize the effects of reducing myostatin activity …

Myostatin, a transforming growth factor–β family member, is a negative regulator of skeletal
muscle growth. To explore the therapeutic potential of targeting myostatin in settings of …

Duchenne muscular dystrophy (DMD) is a lethal, X-linked recessive disease affecting 1 in
3,500 newborn boys for which there is no effective treatment or cure. One novel strategy that …